Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor sitagliptin compared with alpha‐glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate Combination Therapy to Control Diabetes with Sitagliptin‐1): A multicenter, randomized, open‐label, non‐inferiority trial-Reference-Cited by-同舟云学术

Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor sitagliptin compared with alpha‐glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate Combination Therapy to Control Diabetes with Sitagliptin‐1): A multicenter, randomized, open‐label, non‐inferiority trial

Published:2014-09-24 Issue:2 Volume:6 Page:182-191
ISSN:2040-1116
Container-title:Journal of Diabetes Investigation
language:en
Short-container-title:J Diabetes Invest

Author:

Yokoh Hidetaka¹²³,Kobayashi Kazuki²⁴,Sato Yasunori³,Takemoto Minoru¹²,Uchida Daigaku⁵,Kanatsuka Azuma⁶,Kuribayashi Nobuichi⁷,Terano Takashi⁸,Hashimoto Naotake⁹,Sakurai Kenichi¹²,Hanaoka Hideki³,Ishikawa Ko¹²,Onishi Shunichiro¹²,Yokote Koutaro¹²,

Affiliation:

1. Department of Clinical Cell Biology and Medicine Chiba University Graduate School of Medicine Chiba Japan

2. Department of Diabetes, Metabolism and Endocrinology Chiba University Hospital Chiba Japan

3. Chiba University Hospital Clinical Research Center Chiba Japan

4. Department of Regional Disaster Medicine Chiba University Graduate School of Medicine Chiba Japan

5. Hotaruno Central Clinic Chiba Japan

6. Chiba Central Medical Center Chiba Japan

7. Misaki Naika Clinic Chiba Japan

8. Chiba Aoba Municipal Hospital Chiba Japan

9. Tokyo Women's Medical University Yachiyo Medical Center Chiba Japan

Funder

Japanese Ministry of Health, Labour and Welfare